SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

06 May 2026 Evaluate
The Revenue for the quarter ended  March 2026 of Rs. 12105.30 millions grew by 19.39 % from Rs. 10139.40 millions.Net profit showed a marginal rise at Rs. 1972.80 millions for the quarter ended March 2026, as compared to corresponding quarter of last year.Operating profit surged to 3010.30 millions from the corresponding previous quarter of 2675.80 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 12105.30 10139.40 19.39 48459.20 43220.40 12.12 48459.20 43220.40 12.12
Other Income 629.80 179.30 251.25 2044.00 1198.70 70.52 2044.00 1198.70 70.52
PBIDT 3010.30 2675.80 12.50 14023.90 13245.90 5.87 14023.90 13245.90 5.87
Interest -7.40 6.70 -210.45 25.90 46.00 -43.70 25.90 46.00 -43.70
PBDT 3017.70 2669.10 13.06 13998.00 13199.90 6.05 13998.00 13199.90 6.05
Depreciation 441.60 387.60 13.93 1687.70 1399.30 20.61 1687.70 1399.30 20.61
PBT 2576.10 2281.50 12.91 12310.30 11800.60 4.32 12310.30 11800.60 4.32
TAX 603.30 347.20 73.76 2842.10 2631.70 7.99 2842.10 2631.70 7.99
Deferred Tax -70.00 -43.80 59.82 76.00 51.40 47.86 76.00 51.40 47.86
PAT 1972.80 1934.30 1.99 9468.20 9168.90 3.26 9468.20 9168.90 3.26
Equity 250.70 250.70 0.00 250.70 250.70 0.00 250.70 250.70 0.00
PBIDTM(%) 24.87 26.39 -5.77 28.94 30.65 -5.57 28.94 30.65 -5.57

Ajanta Pharma Share Price

3080.00 -13.25 (-0.43%)
07-May-2026 14:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1836.60
Dr. Reddys Lab 1311.90
Cipla 1369.40
Zydus Lifesciences 941.85
Lupin 2457.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×